Journal article
Ibalizumab: an anti-CD4 monoclonal antibody for the treatment of HIV-1 infection
Journal of antimicrobial chemotherapy, v 65(9), pp 1839-1841
Sep 2010
PMID: 20639524
Featured in Collection : UN Sustainable Development Goals @ Drexel
Abstract
The majority of currently available agents for the treatment of HIV-1 infection act by targeting one of several intracellular steps in the viral life cycle. Despite improvements in efficacy and tolerability, the development of viral resistance to these agents is common and significant toxicity and adherence issues still occur. For this reason the development of safe, well tolerated antiviral agents that target a novel step in the viral life cycle remains important. Viral entry into host cells affords several potential extracellular targets for antiretroviral therapy. Ibalizumab, a humanized monoclonal antibody to CD4, the primary host cellular receptor for HIV-1 entry, has been shown to block HIV-1 entry in vitro. Early clinical trials have demonstrated significant antiviral efficacy with a >1 log10 reduction in viral load when given as monotherapy. Its long half-life, which allows weekly dosing, and its administration as an intravenous infusion differentiate it from other currently available antiretroviral agents. These properties may prove useful in allowing improved drug delivery to patients who have had difficulty adhering to daily oral regimens. Its unique mode of action reduces the risk of cross-resistance with currently available antiretroviral agents, with the potential to expand the choices available to treat drug-resistant HIV-1.
Metrics
Details
- Title
- Ibalizumab: an anti-CD4 monoclonal antibody for the treatment of HIV-1 infection
- Creators
- Christopher J. Bruno - Drexel UniversityJeffrey M. Jacobson - Drexel University
- Publication Details
- Journal of antimicrobial chemotherapy, v 65(9), pp 1839-1841
- Publisher
- Oxford University Press
- Resource Type
- Journal article
- Language
- English
- Academic Unit
- Infectious Diseases (and HIV Medicine)
- Web of Science ID
- WOS:000280921400001
- Scopus ID
- 2-s2.0-77955695562
- Other Identifier
- 991019169660404721
UN Sustainable Development Goals (SDGs)
This publication has contributed to the advancement of the following goals:
InCites Highlights
Data related to this publication, from InCites Benchmarking & Analytics tool:
- Web of Science research areas
- Infectious Diseases
- Microbiology
- Pharmacology & Pharmacy